Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome

Blood

Volumn 99, Issue 1, 2002, Pages 245-251

  Zwaan, Christian M ^a   Kaspers, Gertjan J L ^b   Pieters, Rob ^b   Hählen, Karel ^b   Janka Schaub, Gritta E ^b   Van Zantwijk, Christina H ^b   Huismans, Dieuwke R ^b   De Vries, Esther ^b   Rots, Marianne G ^b   Peters, Godefridus J ^b   Jansen, Gerrit ^b   Creutzig, Ursula ^b   Veerman, Anjo J P ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ASPARAGINASE; BUSULFAN; CLADRIBINE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PARONAL; PREDNISOLONE; TIOGUANINE; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOWN SYNDROME; DRUG EXPOSURE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; LYMPHATIC LEUKEMIA; MALE; MONONUCLEAR CELL; NEWBORN; PRIORITY JOURNAL; PROGNOSIS;

EID: 0036098159     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.1.245     Document Type: Article

References (46)

1. Risks of leukaemia and solid tumours in individuals with Down's syndrome
2. Myelodysplasia and acute myelogenous leukemia in Down's syndrome: A report of 40 children of the AML-BFM Study Group
3. Down's syndrome in childhood acute lymphoblastic leukemia: Clinical characteristics and treatment outcome in four consecutive BFM trials: Berlin-Frankfurt-Munster Group
4. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and Down's syndrome: A Pediatric Oncology Group study
5. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia
6. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia
7. A population-based study of 272 children with acute myeloid leukaemia treatedon two consecutive protocols with different intensity: Best outcome in girls, infants, and children with Down's syndrome: Nordic Society of Paediatric Haematology and Oncology (NOPHO)
8. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891
9. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: Experience on Pediatric Oncology Group AML Study 8498
10. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome
11. Leukemic blasts with markers of four cell lineages in Down's syndrome("megakaryoblastic leukemia")
12. Trisomy 21 in childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study
13. Down's syndrome and acute leukemia in children: A population based Nordic study
14. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: Results of an in vitro study
15. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia: Implications for treatment of infants
16. Cellular drug resistance profiles in childhood acute myeloid leukemia: Differences between FAB types and comparison with acute lymphoblastic leukemia
17. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
18. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia
19. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia
20. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay
21. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group
22. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): A report of the French-American-British Cooperative Group
23. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions
24. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood
25. Differential methotrexate resistance in childhood T-versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay
26. Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin
27. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin
28. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: An explanation to differences in clinical outcome
29. Enhanced metabolism of 1-β-D-arabinofuranosylcytosine in Down syndrome cells: A contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia
30. Cystathionine-β-synthase cDNA transfection alters the sensitivity and metabolism of 1-β-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: A model of leukemia in Down syndrome
31. Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing CU/Zn-superoxide dismutase: Implications for Down syndrome
32. Reactive oxygen species and their contribution to pathology in Down syndrome
33. Apoptosis-associated proteins p53 and APO-1/Fas (CD95) in brains of adult patients with Down syndrome
34. Presenility of granulocytes in Down syndrome individuals
35. Increased levels of mutagen-induced chromosome breakage in Down syndrome children with malignancy
36. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome
37. Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not lineage differences in methotrexate accumulation
38. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: Relationship to immunophenotype and ploidy
39. Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia
40. A possible role for methotrexate in the treatment of childhood acute myeloid leukemia, in particular for acute monocytic leukemia
41. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia
42. Acute lymphoblastic leukemia in children
43. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia
44. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia
45. Nineteen cases of the t(1;22)(p13;q13) acute megakaryoblastic leukaemia of infants/children and a review of 39 cases: Report from a t(1;22) study group
46. Biology and outcome of childhood acute megakaryoblastic leukemia: A single institution's experience